Participant Perceptions in a Long-term Clinical Trial of Autosomal Dominant Polycystic Kidney Disease.

Autosomal dominant polycystic kidney disease clinical trials participant experience participant perspective patient-centered care qualitative research trial design

Journal

Kidney medicine
ISSN: 2590-0595
Titre abrégé: Kidney Med
Pays: United States
ID NLM: 101756300

Informations de publication

Date de publication:
Sep 2023
Historique:
medline: 21 8 2023
pubmed: 21 8 2023
entrez: 21 8 2023
Statut: epublish

Résumé

The development of new therapies for autosomal dominant polycystic kidney disease requires clinical trials to be conducted efficiently. In this study, the factors affecting the recruitment and retention of participants enrolled in a 3-year randomized controlled trial in autosomal dominant polycystic kidney disease were investigated. Qualitative study. All participants (N=187) were invited to complete a 16-item questionnaire at the final study visit of the primary trial. Participants were recruited to complete a semistructured interview using purposeful sampling according to age, self-reported gender, and randomization group. Descriptive statistics were used for demographic data and questionnaires. The interview transcripts underwent inductive thematic coding. One hundred and forty-six of the 187 randomized participants (79%) completed the post-trial questionnaire, and 31 of the 187 participants (21%) completed the interview. Most participants (94%) rated their global satisfaction with the trial as high (a score of 8 or more out of 10). Altruism, knowledge gain, and access to new treatments were the main motivators for recruitment. The main reasons for considering leaving the study were concerns about the risk of intervention and family or work issues. Strategies that favored retention included flexibility in attending different study sites, schedule flexibility, staff interactions, and practical support with parking and reminders. The main burden was time away from work with lost wages, and burden associated with magnetic resonance imaging scans and 24-hour urine output collections. The study population was restricted to participants in a single nondrug clinical trial, and the results could be influenced by selection and possible social desirability bias. Participants reported high levels of satisfaction that occurred as a function of the trial meeting participants' expectations. Furthermore, retention was a balance between the perceived benefits and burden of participation. Consideration of these perspectives in the design of future clinical trials will improve their efficiency and conduct. Advances in the clinical practice of autosomal dominant polycystic kidney disease (ADPKD) require affected individuals to voluntarily participate in long-term multicenter randomized controlled trials (RCTs). In this qualitative post hoc study of a 3-year RCT of increased water intake in ADPKD, altruism, knowledge gain, and access to a nondrug treatment positively influenced the decision to volunteer. Ongoing participation was enabled by building flexibility into the study protocol and staff prioritizing a participant's needs during study visits. Although participants completed the required tests, most were considered burdensome. This study highlights the importance of incorporating protocol flexibility into trial design; the preference for interventions with a low risk of adverse effects; and the urgent requirement for robust surrogate noninvasive biomarkers to enable shorter RCTs in ADPKD.

Identifiants

pubmed: 37602144
doi: 10.1016/j.xkme.2023.100691
pii: S2590-0595(23)00109-7
pmc: PMC10432794
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100691

Informations de copyright

© 2023 The Authors.

Références

J Adv Nurs. 2008 Apr;62(1):107-15
pubmed: 18352969
Int J Behav Nutr Phys Act. 2016 Jan 19;13:7
pubmed: 26785637
Am J Kidney Dis. 2022 Jul;80(1):143-146
pubmed: 35597671
BMJ Open. 2018 Jan 21;8(1):e018794
pubmed: 29358433
Eur J Clin Pharmacol. 2022 Oct;78(10):1647-1655
pubmed: 35896802
Nephrology (Carlton). 2019 Dec;24(12):1214-1224
pubmed: 30663163
Clin Transl Sci. 2012 Dec;5(6):452-60
pubmed: 23253666
Nephrol Dial Transplant. 2020 May 1;35(5):755-764
pubmed: 32240311
BMJ Open. 2022 Feb 14;12(2):e059230
pubmed: 35165116
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
BMC Med Res Methodol. 2017 Feb 20;17(1):30
pubmed: 28219336
Nat Rev Drug Discov. 2017 Jun;16(6):381-382
pubmed: 28529317
Adm Policy Ment Health. 2015 Sep;42(5):533-44
pubmed: 24193818
Cochrane Database Syst Rev. 2018 Feb 22;2:MR000013
pubmed: 29468635
AIDS Educ Prev. 2003 Jun;15(3):269-81
pubmed: 12866838
Trials. 2021 May 17;22(1):347
pubmed: 34001229
BMC Nephrol. 2017 Jul 5;18(1):214
pubmed: 28679364
J Clin Epidemiol. 1999 Dec;52(12):1143-56
pubmed: 10580777
Trials. 2018 Jan 29;19(1):76
pubmed: 29378618

Auteurs

Sneha Amin (S)

Michael Stern Laboratory for Polycystic Kidney Disease, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.

Irene Sangadi (I)

Michael Stern Laboratory for Polycystic Kidney Disease, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Department of Renal Medicine, Westmead Hospital, Western Sydney Local Health District, Sydney, Australia.

Margaret Allman-Farinelli (M)

School of Nursing, The University of Sydney, Sydney, Australia.

Sunil V Badve (SV)

St George Hospital, Sydney, Australia.
The George Institute for Global Health, University of New South Wales, Sydney, Australia.

Neil Boudville (N)

Sir Charles Gairdner Hospital, Perth, Australia.
Medical School, University of Western Australia, Perth, Australia.

Helen Coolican (H)

Polycystic Kidney Disease Australia, Roseville, Australia.

Susan Coulshed (S)

North Shore Nephrology, Sydney, Australia.

Sheryl Foster (S)

Department of Radiology, Westmead Hospital, Western Sydney Local Health District, Sydney, New South Wales.
Discipline of Medical Imaging Science, Sydney School of Health Sciences, The University of Sydney, Sydney, Australia.

Mangalee Fernando (M)

Department of Renal Medicine, Prince of Wales Hospital, Sydney, Australia.

Imad Haloob (I)

Department of Renal Medicine, Bathurst Hospital, Bathurst, Australia.

David C H Harris (DCH)

Michael Stern Laboratory for Polycystic Kidney Disease, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Department of Renal Medicine, Westmead Hospital, Western Sydney Local Health District, Sydney, Australia.

Carmel M Hawley (CM)

Australasian Kidney Trials Network, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia.
Translational Research Institute, Brisbane, Australia.
Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Australia.

Jane Holt (J)

Department of Renal Medicine, Wollongong Hospital, Wollongong, Australia.

Martin Howell (M)

School of Public Health, The University of Sydney, Sydney, NSW, Australia.

Karthik Kumar (K)

Gosford Nephrology, Gosford, Australia.

David W Johnson (DW)

Australasian Kidney Trials Network, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia.
Translational Research Institute, Brisbane, Australia.
Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Australia.

Vincent W Lee (VW)

Michael Stern Laboratory for Polycystic Kidney Disease, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Department of Renal Medicine, Westmead Hospital, Western Sydney Local Health District, Sydney, Australia.

Jun Mai (J)

Department of Renal Medicine, Liverpool Hospital, Southwestern Sydney Local Health District, Sydney, Australia.

Anna Rangan (A)

School of Nursing, The University of Sydney, Sydney, Australia.

Simon D Roger (SD)

Renal Research, Gosford, Australia.

Kamal Sud (K)

Department of Renal Medicine, Nepean Kidney Research Centre, Nepean Hospital and Nepean Clinical School, The University of Sydney, Sydney, Australia.

Vicente Torres (V)

Translational Polycystic Kidney Disease Center, Mayo Clinic, Rochester, MN.

Eswari Vilayur (E)

Department of Nephrology, John Hunter Hospital, Newcastle, Australia.

Gopala K Rangan (GK)

Michael Stern Laboratory for Polycystic Kidney Disease, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Department of Renal Medicine, Westmead Hospital, Western Sydney Local Health District, Sydney, Australia.

Classifications MeSH